查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1570722

成人疫苗市場：按疫苗類型、適應症和最終用戶分類 - 全球預測 2025-2030

Adult Vaccines Market by Vaccine Type (Inactivated Vaccines, Live Attenuated Vaccines, Subunit Vaccines), Disease Indication (Hepatitis B, Herpes Zoster, Human Papillomavirus (HPV)), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年成人疫苗市場規模為176.3億美元，預計2024年將達到191.1億美元，複合年成長率為8.28%，預計到2030年將達到307.8億美元。

成人疫苗市場包括用於預防成人感染疾病的疫苗的開拓、生產和應用。由於世界人口老化、可預防疾病意識增強以及政府免疫工作等因素，市場正在應對日益成長的疫苗需求。應用包括流感、腦膜炎、HPV 和肝炎疫苗，最終用途範圍從個人健康維護到公共衛生計劃。影響成長的關鍵因素包括政府更加關注衛生政策、疫苗技術的進步以及公眾疾病預防意識的提高。疫苗接種率低的新興市場有許多成長機會，而醫療保健機會的改善將是成長背後的動力。產業公司應專注於與醫療服務提供者和公共衛生機構合作，擴大推廣和教育範圍。然而，疫苗接種猶豫、監管障礙和分銷物流等挑戰可能會限制市場擴張。此外，高昂的研發成本和漫長的核准流程也帶來了重大挑戰。為了克服這些問題，對無針系統等創新給藥技術的投資以及對組合疫苗的研究可能是潛在的成長途徑。此外，針對個人免疫系統變化的個人化疫苗可能會徹底改變市場。成人疫苗市場的性質是動態的，受到生物醫學不斷進步和不斷變化的全球健康需求的推動。永續的業務成長需要相關人員參與強力的研究和開發，培養更有效的分銷管道的夥伴關係，並實施適應策略以應對不斷變化的社會需求和監管條件。透過專注於提高疫苗的可用性和效率並投資於促進疫苗快速開發和分配的技術，市場可以克服挑戰並抓住成長機會。

主要市場統計
基準年[2023] 176.3億美元
預測年份 [2024] 191.1億美元
預測年份 [2030] 307.8億美元
複合年成長率（%） 8.28%

市場動態：揭示快速發展的成人疫苗市場的關鍵市場洞察

供需的動態交互作用正在改變成人疫苗市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，以及如何減輕消費行為及其對製造成本的影響及其對採購趨勢的影響。

波特五力：駕馭成人疫苗市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解成人疫苗市場的外部影響

外部宏觀環境因素在塑造成人疫苗市場的表現動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解成人疫苗市場的競爭格局

對成人疫苗市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣成人疫苗市場供應商的績效評估

FPNV定位矩陣是評估成人疫苗市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製成人疫苗市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，成人疫苗市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告提供了涵蓋主要焦點細分市場的全面市場分析。

1. 市場滲透率：對當前市場環境的詳細回顧。

2. 市場開拓：辨識新興市場的成長機會，評估現有產業的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢視市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 擴大衛生基礎設施和獲得疫苗接種服務的機會
      • 預防醫學對個人和社區日益重要
      • 新的疫苗可預防疾病和變種的出現
    • 抑制因素
      • 疫苗開發和分銷的高成本限制了市場範圍
    • 機會
      • 與旅遊業相關人員合作，推廣旅行疫苗並確保旅行者健康
      • 針對老年族群的綜合免疫計劃，以提高疫苗接種覆蓋率
    • 任務
      • 嚴格的政府監管和漫長的核准流程阻礙了疫苗市場的擴張
  • 市場區隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章 成人疫苗市場：依疫苗類型

  • 介紹
  • 去活化疫苗
    • 裂解病毒疫苗
    • 全病毒疫苗
  • 減毒活疫苗
  • 次單位疫苗
    • 多醣體疫苗
    • 蛋白質次單元疫苗
  • 類毒素疫苗

第7章 成人疫苗市場：依適應症分類

  • 介紹
  • B型肝炎
  • 帶狀皰疹
  • 人類乳突病毒 (HPV)
  • 流感
  • 肺炎鏈球菌感染

第8章 成人疫苗市場：依最終使用者分類

  • 介紹
  • 診所
  • 居家醫療
  • 醫院
  • 疫苗接種中心

第9章美洲成人疫苗市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區成人疫苗市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲成人疫苗市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-535C6291878F

The Adult Vaccines Market was valued at USD 17.63 billion in 2023, expected to reach USD 19.11 billion in 2024, and is projected to grow at a CAGR of 8.28%, to USD 30.78 billion by 2030.

The adult vaccines market encompasses the development, production, and application of vaccines aimed at preventing infectious diseases in adults. This market addresses the increasing necessity for vaccination due to factors such as the aging global population, rising awareness about preventable diseases, and governmental immunization initiatives. The application scope includes vaccines against influenza, meningitis, HPV, and hepatitis, with end-uses ranging from individual health maintenance to public health programs. Key factors influencing growth include heightened governmental focus on healthcare policies, advances in vaccine technology, and the public's growing awareness of disease prevention. Opportunities abound in emerging markets with low vaccination coverage, where increasing healthcare access can drive growth. Industry players should focus on collaboration with healthcare providers and public health organizations to expand outreach and education. However, challenges such as vaccine hesitancy, regulatory hurdles, and distribution logistics can limit market expansion. Furthermore, high R&D costs and time-consuming approval processes pose significant challenges. To overcome these, investment in innovative delivery technologies, such as needle-free systems, and research into combination vaccines can offer potential growth avenues. Additionally, personalized vaccines that cater to individual immune system variations could revolutionize the market. The nature of the adult vaccine market is dynamic, driven by constant advancements in biomedical science and evolving global health demands. For sustainable business growth, stakeholders should engage in robust R&D, foster partnerships for more effective distribution channels, and implement adaptive strategies to address fluctuating societal needs and regulatory landscapes. By focusing on improving vaccine accessibility and efficiency, and investing in technologies that facilitate rapid vaccine development and distribution, the market can navigate its challenges and harness opportunities for growth.

KEY MARKET STATISTICS
Base Year [2023] USD 17.63 billion
Estimated Year [2024] USD 19.11 billion
Forecast Year [2030] USD 30.78 billion
CAGR (%) 8.28%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Adult Vaccines Market

The Adult Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Expansion of healthcare infrastructure and access to vaccination services
    • Growing emphasis on preventive healthcare among individuals and communities
    • Emergence of new vaccine-preventable diseases and variants
  • Market Restraints
    • High costs associated with vaccine development and distribution limit market reach
  • Market Opportunities
    • Collaborations with travel industry stakeholders to promote travel vaccines and ensure traveler health
    • Comprehensive immunization programs targeting the aging population to increase vaccine uptake
  • Market Challenges
    • Stringent government regulations and lengthy approval processes hinder vaccine market expansion

Porter's Five Forces: A Strategic Tool for Navigating the Adult Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Adult Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Adult Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Adult Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Adult Vaccines Market

A detailed market share analysis in the Adult Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Adult Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Adult Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Adult Vaccines Market

A strategic analysis of the Adult Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Adult Vaccines Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca, Bharat Biotech, BioNTech, CSL Limited, CureVac, Dynavax Technologies, Emergent BioSolutions, GlaxoSmithKline, Inovio Pharmaceuticals, Johnson & Johnson, Merck & Co., Moderna, Novavax, Pfizer, Sanofi, Seqirus, Serum Institute of India, Sinovac Biotech, Valneva SE, and Vaxart.

Market Segmentation & Coverage

This research report categorizes the Adult Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Vaccine Type, market is studied across Inactivated Vaccines, Live Attenuated Vaccines, Subunit Vaccines, and Toxoid Vaccines. The Inactivated Vaccines is further studied across Split Virus Vaccines and Whole Virus Vaccines. The Subunit Vaccines is further studied across Polysaccharide Vaccines and Protein Subunit Vaccines.
  • Based on Disease Indication, market is studied across Hepatitis B, Herpes Zoster, Human Papillomavirus (HPV), Influenza, and Pneumococcal Disease.
  • Based on End User, market is studied across Clinics, Homecare Settings, Hospitals, and Vaccination Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Expansion of healthcare infrastructure and access to vaccination services
      • 5.1.1.2. Growing emphasis on preventive healthcare among individuals and communities
      • 5.1.1.3. Emergence of new vaccine-preventable diseases and variants
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with vaccine development and distribution limit market reach
    • 5.1.3. Opportunities
      • 5.1.3.1. Collaborations with travel industry stakeholders to promote travel vaccines and ensure traveler health
      • 5.1.3.2. Comprehensive immunization programs targeting the aging population to increase vaccine uptake
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government regulations and lengthy approval processes hinder vaccine market expansion
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Adult Vaccines Market, by Vaccine Type

  • 6.1. Introduction
  • 6.2. Inactivated Vaccines
    • 6.2.1. Split Virus Vaccines
    • 6.2.2. Whole Virus Vaccines
  • 6.3. Live Attenuated Vaccines
  • 6.4. Subunit Vaccines
    • 6.4.1. Polysaccharide Vaccines
    • 6.4.2. Protein Subunit Vaccines
  • 6.5. Toxoid Vaccines

7. Adult Vaccines Market, by Disease Indication

  • 7.1. Introduction
  • 7.2. Hepatitis B
  • 7.3. Herpes Zoster
  • 7.4. Human Papillomavirus (HPV)
  • 7.5. Influenza
  • 7.6. Pneumococcal Disease

8. Adult Vaccines Market, by End User

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Homecare Settings
  • 8.4. Hospitals
  • 8.5. Vaccination Centers

9. Americas Adult Vaccines Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Adult Vaccines Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Adult Vaccines Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AstraZeneca
  • 2. Bharat Biotech
  • 3. BioNTech
  • 4. CSL Limited
  • 5. CureVac
  • 6. Dynavax Technologies
  • 7. Emergent BioSolutions
  • 8. GlaxoSmithKline
  • 9. Inovio Pharmaceuticals
  • 10. Johnson & Johnson
  • 11. Merck & Co.
  • 12. Moderna
  • 13. Novavax
  • 14. Pfizer
  • 15. Sanofi
  • 16. Seqirus
  • 17. Serum Institute of India
  • 18. Sinovac Biotech
  • 19. Valneva SE
  • 20. Vaxart

LIST OF FIGURES

  • FIGURE 1. ADULT VACCINES MARKET RESEARCH PROCESS
  • FIGURE 2. ADULT VACCINES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ADULT VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ADULT VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ADULT VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ADULT VACCINES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ADULT VACCINES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ADULT VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ADULT VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ADULT VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ADULT VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ADULT VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ADULT VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ADULT VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ADULT VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ADULT VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ADULT VACCINES MARKET DYNAMICS
  • TABLE 7. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ADULT VACCINES MARKET SIZE, BY SPLIT VIRUS VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ADULT VACCINES MARKET SIZE, BY WHOLE VIRUS VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ADULT VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ADULT VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ADULT VACCINES MARKET SIZE, BY PROTEIN SUBUNIT VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ADULT VACCINES MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ADULT VACCINES MARKET SIZE, BY HUMAN PAPILLOMAVIRUS (HPV), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ADULT VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ADULT VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ADULT VACCINES MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ADULT VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINATION CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES ADULT VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 238. ADULT VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 239. ADULT VACCINES MARKET, FPNV POSITIONING MATRIX, 2023